Account
Newsletter
17.02.2023
PMA Insights: Week 7

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
08.02.2023
First Adalimumab Biosimilar Launch in the USA

The first adalimumab (branded Humira) biosimilar, Amjevita, has been launched in the US by pharmaceu...

Read more
Articles
25.10.2022
How is International Reference Pricing used within...

We discuss the advantages and disadvantages of using international reference pricing for consistent ...

Read more
Articles
18.10.2022
What are the pricing considerations when launching...

We explore the pricing dynamics of biosimilars, which depend on the type of biosimilar, its indicati...

Read more
Articles
12.10.2022
How important is HTA when launching a biosimilar i...

The short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...

Read more
Insider Insights
05.10.2022
Germany: Experts criticise the GKV’s financial s...

On 28th September there was a two-hour public hearing on the GKV Financial Stabilisation Act. There ...

Read more
Insider Insights
23.08.2022
Inflation reduction act aims to reduce healthcare

The legislation is an updated, smaller version of The Build Back Better Act (BBBA) which the US Sena...

Read more
Insider Insights
26.04.2022
List of similar biological groups

Legislation published in the Journal Officiel on 14th April 2022 establishes a first list of similar...

Read more
Articles
06.09.2021
Strategies to navigate patent expiry

Patents are usually only valid for around 20 years however, as patenting occurs early in the R&D pro...

Read more
Articles
21.06.2021
UK the next hub for Biosimilars

Biosimilars could be launching a lot earlier in the UK than the EU thanks to new guidance, improved ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.